← SynDRA
VIGABATRIN
SynDRA canonical compound SYN0003542 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · Rx/OTC |
| Primary target(s) | ABAT |
| Mechanism of action | GABA aminotransferase inhibitor |
| Indication | seizures | spasms |
| Disease area | neurology/psychiatry |
All known targets
Mechanisms of action (all sources)
- GABA aminotransferase inhibitor
- ABAT INHIBITOR
- Gamma-amino-N-butyrate transaminase inhibitor
- ABAT IRREVERSIBLE INHIBITOR
- SLC32A1 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ADORA1
- HRH3
- HTR2A
- HTR2B
- HTR2C
- HTR3A
- KCNH2
- MAOA
- MC3R
- MC4R
- MLNR
- NPY1R
- NR1I2
- NR3C1
- OPRD1
- OPRK1
- OPRM1
- PDE3A
- PDE4D
- PGR
- PTGS2
- SAMHD1
- SLC29A1
- SLC6A2
- SLC6A3
- SLC6A4
- SLCO1B1
- SLCO1B3
- TBXA2R
- HTR1A
- HRH2
- ADORA2A
- HRH1
- ADORA3
- ADRA1A
- ADRA2A
- ADRA2B
- ADRA2C
- ADRB1
- ADRB2
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Anti-epileptic Agent
- Anticonvulsants
- Central Nervous System Agents
- Enzyme Inhibitors
- GABA Agents
- Neurotransmitter Agents
ATC classes
Cross-references
Synonyms
- SABRIL
- Sabril
- VIGADRONE
- VIGAFYDE
- VIGPODER
- Vigadrone
- Vigafyde
- Vigpoder
- (+/-)-4-Amino-5-hexenoic acid
- sabril
- vigabatrin hydrochloride
- vigabatrin HCl
- Vigabatrine
- Vigabatrina
- 5-hexenoic acid, 4-amino-
- Gamma-vinyl gaba
- Vinyl gamma-aminobutyric acid
- CPP-109
- MDL 71,754
- MDL-71754
- RMI-71754
- Kigabeq
- GVG
- Sabrilex
- Vigabatrinum
- Aventis Brand of Vigabatrin
- Gamma-Vinyl-GABA
- Gamma-Vinyl-gamma-Aminobutyric Acid
- Hoechst Brand of Vigabatrin
- Vigabatrin Aventis Brand
- Vigabatrin Hoechst Brand
- Vigabatrin Yamanouchi Brand
- Vigabatrina [Spanish]
- Vigabatrine [French]
- Vigabatrinum [Latin]
- Yamanouchi Brand of Vigabatrin
- M071754
Reported adverse events
- Vision loss
- Depression
- Rash
- Arthralgia
- Dizziness
- Fatigue
- Headache
- Nausea
- Thirst
- Vomiting
- Abdominal pain
- Acute psychosis
Look up VIGABATRIN in the interactive SynDRA portal →